129 related articles for article (PubMed ID: 31966916)
1. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers.
Mizrahi JD; Gunchick V; Mody K; Xiao L; Surapaneni P; Shroff RT; Sahai V
World J Gastrointest Oncol; 2020 Jan; 12(1):83-91. PubMed ID: 31966916
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
Roussot N; Vincent J; Palmier R; Constantin G; Bengrine L; Fumet JD; Ghiringhelli F
Front Oncol; 2023; 13():1293670. PubMed ID: 38098503
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients.
Caparica R; Lengelé A; Bekolo W; Hendlisz A
Autops Case Rep; 2019; 9(2):e2019087. PubMed ID: 31528622
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
5. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Agarwal R; Sendilnathan A; Siddiqi NI; Gulati S; Ghose A; Xie C; Olowokure OO
J Gastrointest Oncol; 2016 Dec; 7(6):996-1003. PubMed ID: 28078124
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario.
Seung SJ; Saherawala H; Syed I; Shephard C; Clouthier DL; Chen E
J Gastrointest Oncol; 2023 Aug; 14(4):1806-1816. PubMed ID: 37720427
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
9. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
10. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Cosgrove DP; Reese ES; Fulcher NM; Bobiak SS; Lamy FX; Allignol A; Boyd M; Mahmoudpour SH
Cancer Med; 2023 Feb; 12(4):4195-4205. PubMed ID: 36263922
[TBL] [Abstract][Full Text] [Related]
12. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H; Ogimi T; Chan LF; Kamei Y
Oncology; 2020; 98(9):637-642. PubMed ID: 32474564
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
16. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
17. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
18. Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers.
Allo G; Can AD; Wahba R; Vogel N; Goeser T; Kütting F; Waldschmidt D
Mol Clin Oncol; 2022 Feb; 16(2):52. PubMed ID: 35070301
[TBL] [Abstract][Full Text] [Related]
19. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation.
Liu Y; Luan L; Wang X
Onco Targets Ther; 2015; 8():1061-8. PubMed ID: 25999741
[TBL] [Abstract][Full Text] [Related]
20. Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Doherty MK; McNamara MG; Aneja P; McInerney E; Moignard S; Horgan AM; Jiang H; Panzarella T; Jang R; Dhani N; Hedley D; Knox JJ
J Gastrointest Oncol; 2017 Apr; 8(2):352-360. PubMed ID: 28480074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
